{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:39:50Z","timestamp":1784875190129,"version":"3.55.0"},"reference-count":26,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3317,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.01004.x","type":"journal-article","created":{"date-parts":[[2006,8,2]],"date-time":"2006-08-02T23:33:35Z","timestamp":1154561615000},"page":"45-51","source":"Crossref","is-referenced-by-count":88,"title":["Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy"],"prefix":"10.1155","volume":"61","author":[{"given":"\u015e.","family":"Aktaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Akarsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130.","family":"Erba\u011fci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Araz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Okumu\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kartal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2006,8,2]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.1997.7.885","article-title":"Quality of life in patients with Graves\u2019 ophthalmopathy is markedly decreased measurement by the medical outcomes study instrument","volume":"7","author":"Gerding","year":"1997","journal-title":"Thyroid"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB2|cit2","first-page":"168","article-title":"Management of Graves'ophthalmopathy: reality and perspectives","volume":"21","author":"Bartelena","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/eje.0.1480491","article-title":"Multi-center study on the characteristics and treatment strategies of patients with Graves\u2019 orbitopathy: the first European Group on Graves\u2019 Orbitopathy experience","volume":"148","author":"Prummel","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"Mourtis","year":"1997","journal-title":"Clin Endocrinol"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF03345277","article-title":"Novel aspects of immunosuppressive and radiotherapy management of Graves\u2019 ophthalmopathy","volume":"27","author":"Marcocci","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1530\/acta.0.1160513","article-title":"Treatment of Graves\u2019 ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy","volume":"116","author":"Nagayama","year":"1987","journal-title":"Acta Endocrinol"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1507\/endocrj.40.63","article-title":"Intravenous methylprednisolone pulse therapy for Graves\u2019 ophthalmopathy","volume":"40","author":"Hiromatsu","year":"1993","journal-title":"Endocr J"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1507\/endocrj.43.689","article-title":"High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy","volume":"43","author":"Tagami","year":"1996","journal-title":"Endocr J"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-978843","article-title":"Intravenous methylprednisolone pulse therapy in the treatment of Graves'ophthalmopathy","volume":"30","author":"Matejka","year":"1998","journal-title":"Horm Metab Res"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0021-5155(02)00544-0","article-title":"Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves\u2019 ophthalmopathy","volume":"46","author":"Ohtsuka","year":"2002","journal-title":"Jpn J Ophthalmol"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9394(02)01970-0","article-title":"Effect of steroid pulse therapy with and without orbital radiotherapy on Graves\u2019 ophthalmopathy","volume":"135","author":"Ohtsuka","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous vs. oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/thy.1998.8.539","article-title":"The measurement of change in Graves\u2019 ophthalmopathy","volume":"8","author":"Gorman","year":"1998","journal-title":"Thyroid"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","article-title":"Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy","volume":"16","author":"Bahn","year":"1987","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bjo.88.1.75","article-title":"Assessing quality of life in Australian patients with Graves\u2019 ophthalmopathy","volume":"88","author":"Park","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1136\/bmj.297.6663.1574","article-title":"Intravenous methylprednisolone in the treatment of Graves\u2019 ophthalmopathy","volume":"297","author":"Kendall-Taylor","year":"1988","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB19|cit19","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1034\/j.1600-0420.2002.800316.x","article-title":"High dose intravenous methylprednisolone pulse therapy vs. oral prednisone for thyroid-associated ophthalmopathy","volume":"80","author":"Kauppinen-Makelin","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343835","article-title":"High-dose intravenous corticosteroid therapy for Graves\u2019 ophthalmopathy","volume":"24","author":"Macchia","year":"2001","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB22|cit22","first-page":"CR477","article-title":"The use of corticosteroids vs. other treatments for Graves\u2019 ophthalmopathy: a quantitative evaluation","volume":"9","author":"Abalkhail","year":"2003","journal-title":"Med Sci Monit"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/thy.1997.7.579","article-title":"Intravenous immunoglobulin vs. corticosteroid in treatment of Graves\u2019 ophthalmopathy","volume":"7","author":"Baschieri","year":"1997","journal-title":"Thyroid"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/thy.2000.10.521","article-title":"Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease","volume":"10","author":"Weissel","year":"2000","journal-title":"Thyroid"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1530\/eje.0.1380368","article-title":"Effects of smoking on thyroid function","volume":"138","author":"Utiger","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1742-1241.2006.01004.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF03345276","article-title":"Relationship between cigarette smoking and Graves\u2019 ophthalmopathy","volume":"27","author":"Hegedius","year":"2004","journal-title":"J Endocrinol Invest"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.01004.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.01004.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:31Z","timestamp":1643349871000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.01004.x"}},"subtitle":["IVGC vs. OGC in Graves\u2019 ophthalmopathy"],"short-title":[],"issued":{"date-parts":[[2006,8,2]]},"references-count":26,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01004.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8,2]]}}}